Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

The Feinberg School team has identified this bouncer, a protein called P21, which prevents immune cells from launching into their destructive rampage through the cartilage and bone. When the scientists developed and injected an imitation of the protein into an animal model of rheumatoid arthritis, the disease process was halted.

"The bouncer molecule stopped the immune cells from going crazy," said lead author Harris Perlman, associate professor of rheumatology at Northwestern's Feinberg School. "Imagine destructive customers in a bar, and the bouncer says, 'You are going to behave!' That's P21. This discovery opens up a new avenue for future therapies, which are greatly needed for rheumatoid arthritis."

Previous research by the Feinberg team showed people with rheumatoid arthritis were low in P21, but the protein's role was unknown. The new study, which will be published in the journal Arthritis & Rheumatism, reveals the protein's vital role in keeping the immune cells in check.

Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said.

To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21. He slipped each peptide into a "ghostlike" molecule that he injected into mice with a rheumatoid arthritis-like disease. The molecule secretly infiltrated the immune cells. After the seven-day trial, one of the tested peptides had calmed the overactive immune cells without toxic effects. Next, Perlman plans a 30-day study with the same peptide to monitor efficacy and toxicity over a longer period of time.

Existing treatments for rheumatoid arthritis include low-level chemotherapy and steroids. These are not always effective, however, and they are frequently accompanied by side effects. A newer class of therapy, which is sometimes used in combination with chemotherapy and steroids, is biologic response modifiers. These are antibodies or other proteins that reduce the inflammation produced by the hyperactive immune cells. These biologics don't work for everyone, though, and can be associated with side effects including the risk of infection.

  • Additional
  • References
  • Citations

Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of others, such as bowel and breast cancers. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk.

TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept.

The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs.

The studies were drawn from an extensive trawl of clinical research databases, and findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall.

Two studies indicated that there was no evidence that patients taking TNF inhibitors over the long term were at increased risk of cancer either. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors.

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors were 79% more likely to develop a melanoma than patients not taking these drugs.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add.

Provided by British Medical Journal (news : web)

One of the most famous American artists is Thomas Chambers. If she could kick the ball they way she liked to kick me in the knee, I'd see to it she played for my team every time.The painting that has touched me the most features a sad little girl and is called A Letter From My Mother. It's pretty funny to me that when we were growing up, she'd cry because she wasn't allowed to play football with us.There is a subcategory of folk art paintings since I was a child. It's a beautiful painting but it's just too depressing to hang anywhere. It's called Alligator Fisher and I'm thinking about getting because it reminds me of my cajun heritage, most of my family is from Louisiana. I have a friend who collects these and I found one of a woman reclining in a hammock. It's of a swamp house on a bayou and has a Louisiana feel to it. It's called First Trolley to Van Nuys and shows the center of a town filled with people. I don't know whose smile is bigger, the one in the painting or the one on my face every time I look at it. When she died, she left me the painting and it hangs.....

He slipped each peptide into a "ghostlike" molecule that he injected into mice with a rheumatoid arthritis-like disease.To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21. But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors over the long term were at increased risk of cancer either. "This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors.Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said. These are not always effective, however, and they are frequently accompanied by side effects. Additional References Citations Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates I don't particularly care for his art. It's of a swamp house on a bayou and has a Louisiana feel to it. I have a friend who collects these and I found one of a woman reclining in a hammock. It's called Alligator Fisher and I'm thinking about getting because it reminds me of my cajun heritage, most of my family is from Louisiana. It is done in vibrant colors and also depicts the buildings in the market like an ice cream parlor and the Hotel Van Nuys. It was painted in 1988 by Reverend Howard Finster and is done in enamel. Maybe it's because I spent a lot of time with my grandmother and her house was full of them. It's too bad my parents didn't let her play football with us.The painting that has touched me the most features a sad little girl and is called A Letter From My Mother. I'll find someone to give it to. When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle. I don't know whose smile is bigger, the one in the painting or the one on my face every time I look at it. It's a beautiful painting but it's just too depressing to hang anywhere. One of my favorites that she had was done by John Roeder. She favors animal prints, and I found one that depicts leopards and gave it to her for her birthday.I have loved folk art paintings since I was a child. It's pretty funny to me that when we were growing up, she'd cry because she wasn't allowed to play football with the boys and I used to tease her relentlessly and pull her pigtails whenever I got the chance. She looked so relaxed, that I could imagine

rthritis medicine athritis medicine arhritis medicine artritis medicine arthitis medicine arthrtis medicine arthriis medicine arthrits medicine arthriti medicine arthritis edicine arthritis mdicine arthritis meicine arthritis medcine arthritis mediine arthritis medicne arthritis medicie arthritis medicin srthritis medicine aethritis medicine atthritis medicine arrhritis medicine aryhritis medicine artgritis medicine artjritis medicine artheitis medicine arthtitis medicine arthrutis medicine arthrotis medicine arthriris medicine arthriyis medicine arthritus medicine arthritos medicine arthritia medicine arthritid medicine arthritis nedicine arthritis mwdicine arthritis mrdicine arthritis mesicine arthritis meficine arthritis meducine arthritis medocine arthritis medixine arthritis medivine arthritis medicune arthritis medicone arthritis medicibe arthritis medicime arthritis medicinw arthritis medicinr rathritis medicine atrhritis medicine arhtritis medicine artrhitis medicine arthirtis medicine arthrtiis medicine arthriits medicine arthritsi medicine arthriti smedicine arthritis emdicine arthritis mdeicine arthritis meidcine arthritis medciine arthritis mediicne arthritis medicnie arthritis medicien arthritis medicin aarthritis medicine arrthritis medicine artthritis medicine arthhritis medicine arthrritis medicine arthriitis medicine arthrittis medicine arthritiis medicine arthritiss medicine arthritis mmedicine arthritis meedicine arthritis meddicine arthritis mediicine arthritis mediccine arthritis mediciine arthritis medicinne arthritis medicinee
Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

The Feinberg School team has identified this bouncer, a protein called P21, which prevents immune cells from launching into their destructive rampage through the cartilage and bone. When the scientists developed and injected an imitation of the protein into an animal model of rheumatoid arthritis, the disease process was halted.

"The bouncer molecule stopped the immune cells from going crazy," said lead author Harris Perlman, associate professor of rheumatology at Northwestern's Feinberg School. "Imagine destructive customers in a bar, and the bouncer says, 'You are going to behave!' That's P21. This discovery opens up a new avenue for future therapies, which are greatly needed for rheumatoid arthritis."

Previous research by the Feinberg team showed people with rheumatoid arthritis were low in P21, but the protein's role was unknown. The new study, which will be published in the journal Arthritis & Rheumatism, reveals the protein's vital role in keeping the immune cells in check.

Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said.

To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21. He slipped each peptide into a "ghostlike" molecule that he injected into mice with a rheumatoid arthritis-like disease. The molecule secretly infiltrated the immune cells. After the seven-day trial, one of the tested peptides had calmed the overactive immune cells without toxic effects. Next, Perlman plans a 30-day study with the same peptide to monitor efficacy and toxicity over a longer period of time.

Existing treatments for rheumatoid arthritis include low-level chemotherapy and steroids. These are not always effective, however, and they are frequently accompanied by side effects. A newer class of therapy, which is sometimes used in combination with chemotherapy and steroids, is biologic response modifiers. These are antibodies or other proteins that reduce the inflammation produced by the hyperactive immune cells. These biologics don't work for everyone, though, and can be associated with side effects including the risk of infection.

  • Additional
  • References
  • Citations

Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of others, such as bowel and breast cancers. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk.

TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept.

The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs.

The studies were drawn from an extensive trawl of clinical research databases, and findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall.

Two studies indicated that there was no evidence that patients taking TNF inhibitors over the long term were at increased risk of cancer either. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors.

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors were 79% more likely to develop a melanoma than patients not taking these drugs.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add.

Provided by British Medical Journal (news : web)